Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Bladder Cancer

  Free Subscription


12.01.2026

1 ACS Biomater Sci Eng
2 Actas Urol Esp (Engl Ed)
1 Am J Mens Health
1 Ann Med
2 Arch Esp Urol
3 Arch Ital Urol Androl
1 Biomol Biomed
1 bioRxiv
2 BJU Int
1 BMC Urol
1 BMJ Case Rep
1 Cancer Cell Int
1 Cancer Diagn Progn
1 Cancer Imaging
1 Cancer Immunol Res
1 Cancer Med
1 Cancers (Basel)
1 Chem Biol Interact
1 Chin Clin Oncol
1 Clin Exp Med
1 Diagnostics (Basel)
1 Eur Urol Oncol
2 Exp Cell Res
1 Expert Rev Anticancer Ther
1 FASEB J
1 Hinyokika Kiyo
2 Int J Mol Sci
2 Int J Surg Pathol
1 Intern Med
1 J Biomed Sci
2 J Cancer Res Clin Oncol
1 J Clin Med
1 J Nanobiotechnology
1 J Robot Surg
1 JCO Oncol Pract
1 Jpn J Clin Oncol
2 Nat Commun
1 Nat Rev Clin Oncol
1 Oxid Med Cell Longev
1 Proc Natl Acad Sci U S A
1 Radiat Oncol
2 Sci Rep
1 World J Surg Oncol
2 World J Urol
1 Zhongguo Zhong Yao Za Zhi
1 Zhonghua Bing Li Xue Za Zhi


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    ACS Biomater Sci Eng

  1. LI X, Xie J, Song SJ, Ahlquist CSE, et al
    Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.
    ACS Biomater Sci Eng. 2026 Jan 7. doi: 10.1021/acsbiomaterials.5c01546.
    PubMed         Abstract available


    Actas Urol Esp (Engl Ed)

  2. SAOULI A, Contieri R, Quhal F, Hurle R, et al
    Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma
    Actas Urol Esp (Engl Ed). 2026 Jan 5:501917. doi: 10.1016/j.acuroe.2026.501917.
    PubMed         Abstract available

  3. DIANA P, Gallioli A, Uleri A, Mas L, et al
    Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors.
    Actas Urol Esp (Engl Ed). 2026;50:501830.
    PubMed         Abstract available


    Am J Mens Health

  4. SHI G, Zhou X, Yang F, Wang T, et al
    Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.
    Am J Mens Health. 2026;20:15579883251410519.
    PubMed         Abstract available


    Ann Med

  5. ABOU CHAKRA M, Boormans JL, Hayne D, O'Donnell MA, et al
    Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer.
    Ann Med. 2026;58:2612387.
    PubMed        


    Arch Esp Urol

  6. ILKTAC A, Ersoz C, Kalkan S, Dogan B, et al
    Bleeding Risks in Urologic Surgery: A Prospective Analysis of Anticoagulant and Antiaggregant Use in Transurethral Resection of Prostate, Transurethral Resection of Bladder Tumour and Open Prostatectomy.
    Arch Esp Urol. 2025;78:1392-1400.
    PubMed         Abstract available

  7. FU Q, Yan F, Sun Z, Yao Z, et al
    Analysis of Urinary Continence, Complications, and Urodynamic Characteristics Following Orthotopic Ileocaecal Neobladder Reconstruction: A Preliminary Study on Safety and Feasibility.
    Arch Esp Urol. 2025;78:1493-1500.
    PubMed         Abstract available


    Arch Ital Urol Androl

  8. BUZOIANU M, Buhas BA, Abou Chakra M, Ionutas E, et al
    A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
    Arch Ital Urol Androl. 2025;97:14596.
    PubMed         Abstract available

  9. FALABELLA R, Porreca A, Foschi N, Salvaggio A, et al
    Robotic bladder diverticulectomy in patients with bladder diverticulum neoplasia: a single-center study.
    Arch Ital Urol Androl. 2025;97:14467.
    PubMed         Abstract available

  10. PEREIRA JA, Vieira-Brito D, Ferreira AM, Marques R, et al
    Hyperthermic vs normothermic mitomycin C for intermediate-risk NMIBC: a real-world retrospective cohort study.
    Arch Ital Urol Androl. 2025;97:14167.
    PubMed         Abstract available


    Biomol Biomed

  11. ZHANG T, Zhang X, Qian L, Hu C, et al
    Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.
    Biomol Biomed. 2025;26:711-719.
    PubMed         Abstract available


    bioRxiv

  12. PIZZI JR, Adhikari I, Prakash P, Miyamoto H, et al
    Machine-learning-based determination of sex-related bladder cancer biomarkers.
    bioRxiv [Preprint]. 2025 Dec 23:2025.12.20.695175.
    PubMed         Abstract available


    BJU Int

  13. PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
    Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
    BJU Int. 2026;137:323-331.
    PubMed         Abstract available

  14. SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
    Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
    BJU Int. 2026;137:270-281.
    PubMed         Abstract available


    BMC Urol

  15. WANG H, Xiong Y, He T, He M, et al
    MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis.
    BMC Urol. 2026 Jan 8. doi: 10.1186/s12894-026-02046.
    PubMed        


    BMJ Case Rep

  16. ADMIRE K, Gegick S
    Transvascular endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to confirm urothelial carcinoma metastasis to the pulmonary artery.
    BMJ Case Rep. 2026;19:e268157.
    PubMed         Abstract available


    Cancer Cell Int

  17. XU D, Jacob JJ, Wieczorek K, Wang L, et al
    Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.
    Cancer Cell Int. 2026 Jan 8. doi: 10.1186/s12935-025-04117.
    PubMed         Abstract available


    Cancer Diagn Progn

  18. MINATO A, Jojima K, Watanabe S, Sugita Y, et al
    Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
    Cancer Diagn Progn. 2026;6:135-143.
    PubMed         Abstract available


    Cancer Imaging

  19. BAI R, Cai L, Jiang M, Wang C, et al
    Development and validation of MRI-based models to predict lymph node metastasis in bladder cancer: a multi-center study.
    Cancer Imaging. 2026 Jan 7. doi: 10.1186/s40644-025-00984.
    PubMed        


    Cancer Immunol Res

  20. YANG FH, Zhang W, Wang R, Mao S, et al
    Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.
    Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873.
    PubMed         Abstract available


    Cancer Med

  21. WANG J, Lu Q, Jiao P, Jian J, et al
    Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.
    Cancer Med. 2026;15:e71477.
    PubMed         Abstract available


    Cancers (Basel)

  22. JAROMIN M, Kutwin P, Konecki T, Popiela D, et al
    Inflammation Indices as Predictive Markers of Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2025;18:136.
    PubMed         Abstract available


    Chem Biol Interact

  23. LIU P, Zhang L, Zhou Q, Fu Z, et al
    STIM1 N-linked glycosylation promotes arsenic-induced malignant phenotype by activating SOCE in bladder epithelial cells.
    Chem Biol Interact. 2026;424:111866.
    PubMed         Abstract available


    Chin Clin Oncol

  24. YUAN J, Yu S, Zheng J
    Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study.
    Chin Clin Oncol. 2025;14:71.
    PubMed         Abstract available


    Clin Exp Med

  25. LI Y, Zhao B, Gao W, Wu Y, et al
    Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.
    Clin Exp Med. 2026;26:62.
    PubMed        


    Diagnostics (Basel)

  26. JAIN M, Tivtikyan A, Kislyakov D, Rakhmatullin T, et al
    The Diagnostic Performance of a Four-Gene Digital Droplet PCR Panel for Urine Liquid Biopsy in Urothelial Bladder Cancer.
    Diagnostics (Basel). 2025;16:69.
    PubMed         Abstract available


    Eur Urol Oncol

  27. MAY M, Wolff I, Brookman-May S, Burger M, et al
    Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. h
    Eur Urol Oncol. 2026 Jan 3:S2588-9311(25)00341-4. doi: 10.1016/j.euo.2025.
    PubMed        


    Exp Cell Res

  28. WANG Y, Liu H, Wang T, Yang Y, et al
    GLRX5 is a prognostic marker in bladder cancer and correlates with activation of cancer-associated fibroblasts in the tumor microenvironment.
    Exp Cell Res. 2026;455:114884.
    PubMed         Abstract available

  29. HE K, Lin C, Wang H, Wu H, et al
    The circ-GLG1/miR-346/KCNJ9 axis drives malignant progression of bladder cancer by modulating KCNJ9 expression.
    Exp Cell Res. 2026;455:114885.
    PubMed         Abstract available


    Expert Rev Anticancer Ther

  30. YU EM, Linville L, Hwang MW, Kim Y, et al
    Harnessing genomic profiling for improved urothelial cancer outcomes.
    Expert Rev Anticancer Ther. 2026;26:93-104.
    PubMed         Abstract available


    FASEB J

  31. JIN Z, Yang W, Peng Y, Ma L, et al
    HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened.
    FASEB J. 2026;40:e71388.
    PubMed         Abstract available


    Hinyokika Kiyo

  32. SAITO M, Kakoi N, Izumi M, Aoki H, et al
    [A Case of Verrucous Carcinoma of the Bladder in a Patient with Cerebral Palsy].
    Hinyokika Kiyo. 2025;71:425-428.
    PubMed         Abstract available


    Int J Mol Sci

  33. NAKAGAWA Y, Yamamoto C, Kawajiri H, Watanabe M, et al
    Whole Genome Sequencing of Clinical Mycobacterium bovis BCG in Disseminated Infection with Mycotic Aneurysm and ARDS After Intravesical Therapy: A Case Report.
    Int J Mol Sci. 2025;27:238.
    PubMed         Abstract available

  34. TRILLA-FUERTES L, Pedregosa-Barbas J, Garcia-Fernandez E, Zambrana F, et al
    Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.
    Int J Mol Sci. 2026;27:476.
    PubMed         Abstract available


    Int J Surg Pathol

  35. CHENG AV, Bardell J, Sangoi AR
    Collision of Presumed Primary Urinary Bladder Malignant Melanoma and Invasive Urothelial Carcinoma: A Case Report.
    Int J Surg Pathol. 2026;34:201-206.
    PubMed         Abstract available

  36. KAYAR K, Dogan MB, Karabay E
    A Rare Presentation of Alveolar Soft Part Sarcoma in the Bladder.
    Int J Surg Pathol. 2026;34:158-161.
    PubMed         Abstract available


    Intern Med

  37. HISANAGA E, Sano T, Yokoo H
    Four Metachronous Cancers: Mutation Profiling Can Be Used to Distinguish Multiple Primary Cancers from Metastases.
    Intern Med. 2026;65:183-186.
    PubMed         Abstract available


    J Biomed Sci

  38. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
    High-CD14-expressing urothelial cancer cells foster a neutrophil-rich tumor microenvironment that increases the risk of radiation-promoted distant metastasis.
    J Biomed Sci. 2026;33:2.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  39. HESSE M, Iltzsche M, Nahhas D, Thomas C, et al
    Type I-interferon beta induces a strong anti-tumour response in bladder cancer cells.
    J Cancer Res Clin Oncol. 2026;152:35.
    PubMed         Abstract available

  40. BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
    Retraction Note: High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
    J Cancer Res Clin Oncol. 2026;152:26.
    PubMed        


    J Clin Med

  41. HARSANYI S, Novakova ZV, Neuschlova L, Galbavy S, et al
    Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer.
    J Clin Med. 2026;15:338.
    PubMed         Abstract available


    J Nanobiotechnology

  42. WU Z, Zeng J, Feng L, Zhu X, et al
    Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment.
    J Nanobiotechnology. 2026 Jan 10. doi: 10.1186/s12951-025-03955.
    PubMed         Abstract available


    J Robot Surg

  43. ORAKZAI FK, Mirza W, Khan ME, Iqbal H, et al
    Robot-assisted versus open radical cystectomy with extracorporeal urinary diversion for bladder cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with subgroup analyses by orthotopic neobladder utilisation.
    J Robot Surg. 2026;20:151.
    PubMed        


    JCO Oncol Pract

  44. RAGHAVAN D
    Sad But True: Inconsistent Care for Invasive Bladder Cancer.
    JCO Oncol Pract. 2026 Jan 9:OP2501254. doi: 10.1200/OP-25-01254.
    PubMed        


    Jpn J Clin Oncol

  45. GATELLIER L, Nakata K
    Age-standardized mortality-to-incidence ratio for bladder cancer in the world.
    Jpn J Clin Oncol. 2026;56:115-116.
    PubMed        


    Nat Commun

  46. SINGH P, D'Rozario R, Chakraborty B, Meher S, et al
    Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.
    Nat Commun. 2026 Jan 7. doi: 10.1038/s41467-025-68132.
    PubMed         Abstract available

  47. STURDIVANT MS, Truong AS, Zhou M, Toomer ED, et al
    APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.
    Nat Commun. 2025;17:334.
    PubMed         Abstract available


    Nat Rev Clin Oncol

  48. ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
    Advances in the management of localized bladder cancers.
    Nat Rev Clin Oncol. 2026 Jan 5. doi: 10.1038/s41571-025-01104.
    PubMed         Abstract available


    Oxid Med Cell Longev

  49. CELLULAR LONGEVITY OMA
    RETRACTION: lncRNA OTUD6B-AS1 Exacerbates As(2)O(3)-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2.
    Oxid Med Cell Longev. 2025;2025:9894089.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  50. DARJI S, Qu F, Henager M, Prasad A, et al
    Optimizing mRNA delivery with targeted elastin-like polypeptide-based LENN formulations: Insights into the endocytosis mechanism.
    Proc Natl Acad Sci U S A. 2026;123:e2502486122.
    PubMed         Abstract available


    Radiat Oncol

  51. REMMELINK MJ, El Awadly N, Arbeel-Weening B, Nadorp S, et al
    Correction: Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.
    Radiat Oncol. 2026;21:8.
    PubMed        


    Sci Rep

  52. YE Y, Chen Q, Huang Z, Huang Q, et al
    Preferred surgical strategies for bladder diverticular carcinoma.
    Sci Rep. 2025;16:917.
    PubMed         Abstract available

  53. GUO C, Zhou Y, Liu X, Gao K, et al
    Analysis of the care needs of family caregivers of patients with bladder cancer undergoing urostomy: a cross-sectional study.
    Sci Rep. 2026 Jan 3. doi: 10.1038/s41598-025-34339.
    PubMed         Abstract available


    World J Surg Oncol

  54. DAI P, Chen L, Dong Z, Wang H, et al
    LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.
    World J Surg Oncol. 2026 Jan 7. doi: 10.1186/s12957-025-04171.
    PubMed        


    World J Urol

  55. PATTOU M, Robert G, Gouhizoun O, Guena F, et al
    Persistent lymph node uptake on [18 F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC.
    World J Urol. 2026;44:77.
    PubMed         Abstract available

  56. ROESSLER N, Maiorano BA, Miszczyk M, Miyajima K, et al
    First-line treatments for BCG-naive non-muscle invasive bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2026;44:76.
    PubMed         Abstract available


    Zhongguo Zhong Yao Za Zhi

  57. SHAO YQ, Sheng DY, Guan YJ, Mi EX, et al
    [Mechanism of periplogenin in promoting Nrf2 degradation and inducing ferroptosis to inhibit bladder cancer].
    Zhongguo Zhong Yao Za Zhi. 2025;50:5790-5799.
    PubMed         Abstract available


    Zhonghua Bing Li Xue Za Zhi


  58. [Clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version)].
    Zhonghua Bing Li Xue Za Zhi. 2026;55:7-15.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.